Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Shire plc is reporting that the FDA will allow the company to distribute its treatment for Gaucher disease before FDA approval, to blunt the effect of a shortage of the only drug on the market, Genzyme’s Cerezyme.
UK-based Shire, whose Human Genetic Therapies division is headquartered in Cambridge and Lexington, also released positive Phase 3 data for the Gaucher drug, called velaglucerase alfa. The company also announced that it has begun filing portions of the New Drug Application for the medication, and will finish its submission by the end of this quarter.
Shire officials say they are conducting the largest and most comprehensive set of Phase 3 clinical trials conducted to date for Gaucher disease. More than 100 patients at 24 sites in 10 countries around the world have participated in the clinical studies.
The first trial in the Phase 3 program to be completed was a multicenter, randomized, double-blind, two dose study of velaglucerase alfa in patients with Type 1 Gaucher disease. The primary goal of this study was to evaluate the safety and efficacy of velaglucerase alfa in 25 patients with Type 1 Gaucher disease.
The only Gaucher disease treatment currently on the market is Cerezyme, made by Cambridge-based Genzyme Corp. Genzyme’s production cannot currently meet projected demand following a temporary closure at the company’s manufacturing facility in Allston, due to contamination by a virus. Genzyme has resumed production of the medicine but it takes four months to develop from start to finish.
Gaucher disease results from a specific enzyme deficiency in the body, caused by a genetic mutation received from both parents. The disease involves many organ systems, such as liver, spleen, lungs, brain, metabolism and bone marrow.
Worldwide, the diagnosed population of Gaucher Disease patients is approximately 7,000.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
